<DOC>
	<DOCNO>NCT02583516</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety two different schedule administration vemurafenib combination cobimetinib ( continuous intermittent ) previously untreated BRAFV600- mutation positive patient unresectable locally advanced metastatic melanoma .</brief_summary>
	<brief_title>Clinical Trial Evaluate Efficacy Vemurafenib Combination With Cobimetinib ( Continuous Intermittent ) BRAFV600-mutation Positive Patients With Unresectable Locally Advanced Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>DiseaseSpecific 1 . Patients histologically confirm melanoma , either unresectable stage IIIc stage IV metastatic melanoma . 2 . Patients must naïve treatment locally advance unresectable metastatic disease . 3 . Documentation BRAFV600 mutationpositive status melanoma tumor tissue . 4 . Measurable disease per RECIST v1.1 . 5 . ECOG performance status 0 1 . 6 . Additionally , patient include biomarker sub study meet follow criterion : Consent provide archival tissue biomarker analyse . Consent undergo tumor biopsy . General 7 . Male female patient age major equal 18 year . 8 . Able participate willing give write inform . 9 . Life expectancy mayor igual 12 week . 10 . Adequate hematologic end organ function , within 14 day prior first dose study drug treatment : ANC major equal 1.5 × 109/L . Platelet count major equal 100 × 109/L . Hemoglobin major equal 9 g/dL . Albumin major equal 2.5 g/dL . Bilirubin minor equal 1.5 × upper limit normal ( ULN ) . AST , ALT , alkaline phosphatase minor equal 3 × ULN , follow exception : Patients document liver metastasis : AST and/or ALT minor equal 5 × ULN . Patients document liver bone metastasis alkaline phosphatase minor equal 5 × ULN . Serum creatinine minor equal 1.5 × ULN CrCl major equal 40 mL/min basis measure CrCl 24 hour urine collection . 11 . Female patient childbearing potential male patient partner childbearing potential must agree always use 2 effective form contraception course study least 6 month completion study therapy . 12 . Negative serum pregnancy test within 10 day prior commencement dose woman childbearing potential . 13 . Absence psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup treatment discontinuation schedule . CancerRelated 1 . History prior RAF MEK pathway inhibitor treatment . 2 . Palliative radiotherapy within 14 day prior first dose study treatment . 3 . Major surgery traumatic injury within 14 day prior first dose study treatment . 4 . Active malignancy melanoma could potentially interfere interpretation efficacy measure . Patients previous malignancy within past 3 year exclude except patient resect BCC SCC skin , melanoma insitu , carcinoma insitu cervix , carcinoma insitu breast . History isolated elevation prostatespecific antigen absence radiographic evidence metastatic prostate cancer allow . Exclusion Criteria Based Ocular Function : 5 . History evidence retinal pathology ophthalmologic examination consider risk factor neurosensory retinal detachment , retinal vein occlusion ( RVO ) , neovascular macular degeneration . The risk factor RVO list . Patients exclude follow condition : Uncontrolled glaucoma intraocular pressure &gt; 21 mmHg . Serum cholesterol major equal Grade 2 . Hypertriglyceridemia major equal Grade 2 . Hyperglycemia ( fast ) major equal Grade 2 . Exclusion Criteria Based Cardiac Function : 6 . History clinically significant cardiac dysfunction , include follow : Current unstable angina . Symptomatic congestive heart failure New York Heart Association class 2 high . History congenital long QT syndrome mean ( average triplicate measurement ) QTcF &gt; 450 msec baseline uncorrectable abnormality serum electrolyte ( sodium , potassium , calcium , magnesium , phosphorus ) . If automate , calculation QTcF must do follow formula : QTcF = ( QT interval m ) / [ ( 60 / heart rate bpm ) ) ^ ( 1/3 ) ] Uncontrolled hypertension major equal Grade 2 ( patient history hypertension control antihypertensive minor equal Grade 1 eligible ) . Left ventricular ejection fraction ( LVEF ) institutional low limit normal ( LLN ) 50 % . Exclusion Criteria Based Central Nervous System Function : 7 . Patients active CNS lesion ( include melanomatous meningitis ) exclude . However , patient eligible : All know CNS lesion treat stereotactic therapy surgery , AND There evidence clinical radiographic disease progression CNS major equal 3 week radiotherapy surgery . Whole brain radiotherapy allow , exception patient definitive resection stereotactic therapy radiologically detectable parenchymal brain lesion . General 8 . Current severe , uncontrolled systemic disease . 9 . History malabsorption condition would interfere absorption study drug . 10 . Pregnant lactating . 11 . Unwillingness inability comply study follow procedure . 12 . The following foods/supplements prohibit least 7 day prior initiation study treatment : St. Johns wort hyperforin ( potent cytochrome P450 CYP3A4 enzyme inducer ) . Grapefruit juice ( potent cytochrome P450 CYP3A4 enzyme inhibitor ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>